Börse:
3,164$
0,12%
Echtzeit-Aktienkurs Akebia Therapeutics
Bid:
3,123$
Ask:
3,205$
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 369,82 Mio. EUR (116,89 Mio. x 3,164$) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | - | 79,59 | 0,85 | 1,78 |
| KGV | - | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Akebia Therapeutics Aktie
Börsenkurse Akebia Therapeutics
| Dollar Indikation | 3,123$ | 0 | 3,205$ | 0 | 3,164$ | 0,12% |
| Börse Stuttgart | 2,820€ | 712 | 2,900€ | 688 | 2,860€ | 0,00% |
| Tradegate | 2,820€ | 712 | 2,900€ | 688 | 2,860€ | 0,00% |
| Lang & Schwarz | 2,820€ | 4225 | 2,900€ | 4225 | 2,860€ | 0,70% |
| Euro Indikation | 2,820€ | 0 | 2,900€ | 0 | 2,860€ | 0,00% |
Fundamentaldaten der Akebia Therapeutics Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 207,74 Mio. | -171,93 Mio. | -143,59 Mio. | -2,47 | 0,00% | - | 1,78 |
| 2017 | 177,98 Mio. | -76,91 Mio. | -76,91 Mio. | -1,77 | 0,00% | - | 0,85 |
| 2016 | 1,54 Mio. | -135,75 Mio. | -135,75 Mio. | -3,60 | 0,00% | - | 79,59 |
| 2015 | 0,00 Mio. | -60,72 Mio. | -60,72 Mio. | -2,29 | 0,00% | - | - |
| 2014 | 0,00 Mio. | -37,03 Mio. | -37,03 Mio. | -8,04 | 0,00% | - | - |
| 2013 | 0,00 Mio. | -13,17 Mio. | -13,17 Mio. | -3,43 | 0,00% | - | - |
| 2012 | 0,00 Mio. | -8,20 Mio. | -8,20 Mio. | -0,57 | 0,00% | - | - |
| 2011 | 0,00 Mio. | -15,30 Mio. | -18,27 Mio. | -0,91 | 0,00% | - | - |
Profil der Akebia Therapeutics Aktie
Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Its lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen